NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Recommendation of “Moderate Buy” by Analysts

Posted by Brenda Bartman on May 15th, 2026

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $48.00.

Several brokerages recently weighed in on NAMS. HC Wainwright raised NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. Finally, Guggenheim lifted their price objective on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, February 19th.

Get Our Latest Stock Analysis on NewAmsterdam Pharma

NewAmsterdam Pharma Stock Down 2.3%

Shares of NAMS stock opened at $36.88 on Friday. The company has a 50 day moving average of $32.25 and a 200-day moving average of $34.31. NewAmsterdam Pharma has a 12-month low of $16.78 and a 12-month high of $42.21. The firm has a market cap of $4.24 billion, a P/E ratio of -20.60 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The company had revenue of $3.04 million for the quarter. As a group, equities analysts expect that NewAmsterdam Pharma will post -1.76 EPS for the current year.

Insider Activity at NewAmsterdam Pharma

In related news, CEO Michael H. Davidson sold 443,707 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $33.25, for a total value of $14,753,257.75. Following the completion of the transaction, the chief executive officer directly owned 174,144 shares in the company, valued at approximately $5,790,288. The trade was a 71.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johannes Jacob Piete Kastelein sold 104,467 shares of NewAmsterdam Pharma stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $30.30, for a total transaction of $3,165,350.10. Following the completion of the transaction, the insider owned 69,302 shares of the company’s stock, valued at $2,099,850.60. This represents a 60.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 1,168,286 shares of company stock worth $38,211,967. Corporate insiders own 12.74% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Wells Fargo & Company MN increased its position in shares of NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after buying an additional 300 shares during the period. Geode Capital Management LLC increased its position in shares of NewAmsterdam Pharma by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock valued at $3,590,000 after buying an additional 437 shares during the period. Arizona State Retirement System increased its position in shares of NewAmsterdam Pharma by 3.8% during the third quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $377,000 after buying an additional 483 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of NewAmsterdam Pharma by 5.3% during the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after buying an additional 544 shares during the period. Finally, Farther Finance Advisors LLC increased its position in shares of NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after buying an additional 708 shares during the period. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Company Profile

(Get Free Report)

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.